Interleukin-1 as a therapeutic target in gout.

Détails

ID Serval
serval:BIB_CCD5AB8E4EB6
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Interleukin-1 as a therapeutic target in gout.
Périodique
Current Opinion in Rheumatology
Auteur(s)
Dumusc A., So A.
ISSN
1531-6963 (Electronic)
ISSN-L
1040-8711
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
27
Numéro
2
Pages
156-163
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
PURPOSE OF REVIEW: To give an overview of current evidence for interleukin (IL)-1 blockade in the management of gout.
RECENT FINDINGS: Three IL-1 blockers are currently available for clinical use: anakinra, rilonacept and canakinumab. Recent studies have focused on drugs with a long half-life: rilonacept and canakinumab. For treatment of acute gouty arthritis, three randomized controlled trials (RCTs) showed efficacy of canakinumab with some safety concerns and one RCT failed to show efficacy of rilonacept. For prevention of gout flare when starting uric acid lowering therapy (ULT), four RCTs showed efficacy of rilonacept and one RCT showed efficacy of canakinumab.
SUMMARY: There is sufficient evidence supporting the use of IL-1 blockers for treatment of acute gouty arthritis or for prevention of gout flares when starting ULT in selected patients, with contraindications or intolerance to conventional therapy. More data are needed to assess safety and to specify their use in routine practice.
Pubmed
Web of science
Création de la notice
06/03/2015 20:06
Dernière modification de la notice
03/03/2018 21:29
Données d'usage